Skip to main content

Table 3 Secondary endpoint discrepancies

From: Discrepancies in endpoints between clinical trial protocols and clinical trial registration in randomized trials in oncology

  Number of trials n = 71 (%) Secondary Endpoint Discrepancy n = 45 (%) P Value
Trial Initiation Period
 1994–2005 30 (42) 19 (42) 0.9944
 2006–2010 41 (58) 26 (58)  
Trial Result
 Negative 37 (52) 26 (58) 0.2087
 Positive 34 (49) 19 (42)  
Funding Source
 Non-pharma 33 (46) 18 (40) 0.1499
 Pharma 38 (54) 27 (60)  
Duration of Trial
 < 3 years 30 (42) 21 (47) 0.3220
 ≥ 3 years 41 (58) 24 (53)  
Number of clinical trial protocol non-primary endpointsa
 ≤ 6 36 (51) 19 (42) 0.0600
 > 6 35 (49) 26 (58)  
Protocol Lengtha
 ≤ 34 pages 36 (51) 22 (49) 0.4969
 > 34 pages 35 (49) 23 (51)  
Study Phaseb
 II 10 (14) 7 (16) 0.8984
 III 57 (50) 35 (78)  
Study Intervention
 Systemic 53 (75) 37 (82) 0.0536
 Non-systemic 18 (25) 8 (18)  
Protocol Type
 Full 60 (85) 39 (87) 0.5162
 Appended 11 (15) 6 (13)  
  1. aDichotomized at the median
  2. b4 unspecified trials not included